Expanding its international market is the strategic priority of Cheerland Biotechnology in 2023.

Women are rising as a strong force on the market as creators, investors, and consumers as well.

Pursuing low-carbon consumption is critical for the success of environmental conservation.

China's sci-fi industry experienced steady growth in 2021, with total revenue reaching 82.96 billion yuan ($12 billion), a 50.5% year-on-year increase, according to the 2022 report released at the 2023 annual conference of the China Science Fiction Research Center on Feb. 18.

Following a stint at his uncle's farm in China's Qinghai Province in 2018, seeing the amount of milk, milk products and all dairy-processing wastes, Robert Luo began contemplating how to manage these surpluses.

The ecological value of carbon sinks has been continuously exploited in recent years. How to transform their economic value and help with high-level ecological protection and high-quality economic development has subsequently become a hot topic of conversation.

A-shares are mainly available for trading to Chinese mainland investors, but foreign investment in the companies is allowed under regulation.

The founder of a financial consultancy weighs in on the impact of China’s re-opening and other hot issues

China and Europe will support enterprises flexibly on the path of continuous upgrading to make them the main drivers of post-epidemic economic development in China and Europe.

A high-end hydrogen equipment manufacturing and application demonstration zone is gearing up to meet the hydrogen market demands of Beijing.

Decathlon will launch more innovative and high-quality products to meet people's increasing sports needs and upgraded sports consumption concepts, and grow together with the Chinese market.

TRTCM carries on the techniques, procedures, and dedication of its founders while embracing modernization to expand the applications of traditional medicine.

China Eastern Airlines continues to shoulder corporate social responsibilities and add value in the new era.

The German pharmaceutical giant's plans for China remain long-term and its investment policy unchanged after eight decades despite geopolitics.